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Abstract
Thrombotic thrombocytopenic purpura is an uncommon disease and is rare in systemic lupus
erythematosus. Rarely, patients do not respond to plasma exchange therapy, and treatment options
are limited and often disappointing, thus it is a therapeutic challenge to clinicians. We report a
patient with lupus nephritis who developed refractory thrombotic thrombocytopenic purpura and
was subsequently treated with cyclosporin A. An immediate and sustained response was
demonstrated, and she remained well; eventually she was able to be cyclosporin free after the
acute episode. Cyclosporin A can be a safe and effective therapeutic option in patients with refractory
thrombotic thrombocytopenic purpura.
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C A S E
R E P O R T
CASE REPORT
A 28-year-old woman was diagnosed with lupus nephritis
type IV by renal biopsy (activity index 11/24, chronicity
index 3/12) in December 1998 when she first presented
with nephrotic syndrome. She was treated with
prednisolone and 11 doses of intravenous cyclo-
phosphamide according to the National Institutes of
Health regime. However, heavy proteinuria persisted (11
g/d) and a second renal biopsy was performed on October
30, 2000. Her hemoglobin (Hb) was 12 g/dL with a
normal platelet count of 298 x 109/L. Her creatinine was
98 µmol/L. Her medications included prednisolone 15
mg om, Caltrate (Lederle, Whiltehall) 1500 mg BD, and
furosemide 40 mg BD. The biopsy revealed lupus
nephritis type IV d lesion (activity index 3/24, chronicity
index 6/12).
Three weeks later, on November 21, 2000, she was
admitted with an increase in shortness of breath, ankle
swelling, and a decrease in urine output for several days.
On admission, she was pale and tachypneic, with
generalized edema. Her body temperature was 37oC,
blood pressure was 119/115 mm Hg, and her pulse rate
was 125 bpm. A cardiovascular examination showed
elevated jugular venous pressure and a displaced apex
to the sixth intercostal space 2 cm lateral to the left
midclavicular line; no murmur was detected. A chest
examination showed bilateral basal crepitations.
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computerized tomography of the brain showed neither
hemorrhage nor any space-occupying lesion. In view of
the developing neurological signs along with HUS, the
diagnosis of thrombotic thrombocytopenia purpura
(TTP) was made. She was transferred back from the
intensive care unit after 8 days (Hb 7.3 g/dL, platelet
count 74 x 109/L, LDH 495 U/L). Plasma exchange was
continued with one plasma volume of fresh frozen plasma
per session. The platelet count remained around 69 x
109/L and she was blood-transfusion dependent.
Cryoprecipitate-reduced plasma was used as the
replacement, and the exchange volume was increased to
1.5 times the plasma volume.
On December 20, 2000, 1 month after the patient was
first admitted, her complete blood count showed Hb 8.8
g/dL, platelet count 185 x 109/L, and LDH 222 U/L with
no schistocyte detected in a blood smear. Three times
per week, PE was performed and the response was
sustained for 2 weeks. She was still dialysis dependent,
and a Tenchkoff catheter was inserted on January 12,
2001 for peritoneal dialysis.
The patient remained dependent on PE, and after 35
sessions, a 5-day course of intravenous immune globulin
(IVIG) (0.4 g/kg/d) was given, but the response was
unsatisfactory. The platelet count decreased from 139 to
64 x 109/L and the LDH increased from 268 to 577 U/L.
Daily PE was resumed on January 22, 2001 and
intravenous vincristine 2 mg weekly for 4 weeks was
started on January 30, 2001. During these 4 weeks, the
platelet count stayed around 60 to 90 x 109/L, LDH 500
to 700 U/L, and 6 U of packed cells were given.
The last dose of vincristine was given on February 20,
2001.
Cyclosporin A 5 mg/kg/d per oral was started on February
23, 2001. The platelet count showed an improving trend
in 2 weeks and the LDH level improved. Plasma
exchange sessions were spaced out from three times
weekly to twice weekly and then once weekly. Plasma
exchange was completely discontinued after May 18,
2001, after a total of 86 sessions.
The patient was discharged home and was on continuous
ambulatory peritoneal dialysis. Her platelet count
remained sustained above 150 x  109/L and the
cyclosporin A level was maintained at 80 to 120 µg/L,
whereas prednisolone was later reduced to 15 mg om.
She did not experience any usual side effects from the
cyclosporin.
In October 2001, the patient had an episode of
Pseudomonas aeruginosa peritonitis and an exit-site
Abdominal, neurological, and fundal examinations were
normal. A urinalysis showed a few red blood cells and
the presence of proteinuria. An electrocardiogram
showed sinus tachycardia, and a chest x-ray revealed
cardiomegaly and congested lung fields.
Laboratory studies showed a complete blood picture with
a Hb level of 3.1 g/dL, a white blood count of 9.2 x 109/
L, and a platelet count of 93 x 109/L. A peripheral blood
smear revealed schistocytes and 17% reticulocytes.
Activated partial thromboplastin time, prothrombin time,
and international normalized ration were all normal. A
biochemistry revealed the following: sodium 134 mmol/
L, potassium 4.8 mmol/L, urea 64.4 mmol/L, creatinine
1400 µmol/L, serum albumin 25 g/dL, and total bilirubin
24 µmol/L. Liver enzymes were within the normal range.
An arterial blood gas on the room air showed the
following: pH 7.238, HCO3 12.3 mmol/L, PCO2 2.99
kPa, and PO2 9.83 kPa. Lactate dehydrogenase (LDH)
increased to 2115 U/L (normal range, 110-230 U/L),
haptoglobin levels decreased to less than 0.06 g/L
(normal range, 0.47-1.93 g/L), Coombs test was negative,
and the glucose-6-phosphate dehydrogenase level was
normal.
Urgent ultrasonography of both kidneys with Doppler
s h o w e d  n o r m a l - s i z e d  k i d n e y s  w i t h  p o o r
corticomedullary differentiation without evidence of
obstruction or renal vein thrombosis. Serological data
showed C3 0.66 g/L (normal range, 0.69-1.35 g/L) and
anti-dsDNA 49 IU/mL (normal, <30 IU/mL). Anticardiolipin
antibodies were immunoglobulin G less than 10 Gp U/
mL (normal, <7.2 Gp U/mL), immunoglobulin M 13.1
MPL U/mL (normal, <12.5 MPL U/mL), proteinase 3-
anti-neutrophil cytoplasmic antibodies less than 0.1%
(normal, <0.8%), and myeloperoxidase-anti-neutrophil
cytoplasmic antibodies less than 0.1% (normal, <1%).
Lupus anticoagulant was negative and cryoglobulin was
not detected. Serum serological tests for hepatitis B,
hepatitis C, and human immunodeficiency virus were
all negative. The presumptive diagnosis was hemolytic
uremic syndrome (HUS), and the patient was treated with
daily plasma exchange (PE) with fresh frozen plasma as
replacement solution, together with pulse dose steroids
consisting of methylprednisolone 0.5 g/d for 3
consecutive days followed by oral prednisolone at 30
mg/d. A hemodialysis was also arranged for renal support.
During PE 7 days later, the patient developed two
episodes of generalized tonic clonic convulsion (with
normal serum sodium, ionized calcium, and glucose) and
complicated with tongue bleeding. A plication of the
bleeder was performed, and the patient was transferred
to the intensive care unit for further management. Urgent
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abscess that necessitated the removal of the Tenchkoff
catheter. Cyclosporin was discontinued and her platelet
count remained normal throughout. Her lupus activity
was quiescent and was maintained on prednisolone 10
mg om. Her platelet count remained normal 3 months
afterward at 163 x 109/L.
DISCUSSION
Thrombotic thrombocytopenia purpura, a multisystem
disorder characterized by fever, thrombocytopenic
microangiopathic hemolytic anemia, neurological
symptoms, and kidney involvement, was first recognized
by Moschowitz (1) in 1923 who described a fulminant
and fatal illness characterized by pallor, petechiae, fever,
slight paralysis, and proteinuria in a 16-year-old girl. The
mortality remained high (>90%) until PE was the
treatment of choice in the 1980s. Since then, 80% to 90%
of TTP patients have been successfully treated by PE.
Despite these encouraging results, 10% to 20% still
achieve only transient response or are refractory to PE.
Treatment options with glucocorticosteroid, splenectomy,
vincristine sulfate, and IVIG have been used for resistant
or relapsing patients with variable results.
Thrombotic thrombocytopenia purpura has rarely
been described in association with systemic lupus
erythematosus (SLE). The combination, as in this case,
is uncommon (2), particularly because the patient was
under treatment with immunosuppressive agents. Musio
et al (1), in 1998, reviewed 41 cases of TTP in association
with SLE in the world literature. Three distinct
populations were seen–Group 1 had TTP after SLE
(n = 30, 73%; median age, 35 years); Group 2 with TTP
preceded SLE (n = 6, 15%; median age, 17 years); and
Group 3 had TTP simultaneously with SLE (n = 5, 12%;
median age, 17 years). The primary treatment modality
consisted of PE (68%), plasma infusion alone, steroids
alone (10%), and no therapy (7%). Adjunctive therapy
included steroids, cyclophosphamide, IVIG, vincristine,
splenectomy, and antiplatelet agents. The overall
mortality was 34%. Adjunctive therapy did not seem to
affect mortality.
For the case presented here, we used pulse methyl-
prednisolone, intravenous vincristine, and IVIG as
adjunctive therapy to wean the patient from PE, but this
was unsuccessful. We did not use cyclophosphamide, as
in many reported cases, because she had already received
11 doses of intravenous cyclophosphamide previously.
Cyclosporin A has generally not been used in the
treatment of TTP, because it can induce endothelial
damage and cause TTP. However, there are recent reports
of patients who had failed to respond to PE and
antiplatelet agents and were subsequently treated with
cyclosporin A with an immediate, sustained response,
and were maintained on cyclosporin afterward (3-7). The
mechanism of action of cyclosporin A in TTP is
unknown, but it may be mediated through one of two
separate pathways, or both (6). It may work directly as a
T-cell inactivator. Secondly, an increase in endothelial
nitric oxide activity induced by cyclosporin A may inhibit
platelet aggregation and hence halt the progression.
Despite the multiple therapies used, the response from
this patient was refractory; however, the response with
cyclosporin was immediate and sustained. Cyclosporin
was eventually discontinued and her platelet count
remained normalized. Cyclosporin can be a safe and
effective therapeutic option for patients with refractory
TTP.
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